Calcium dobesilate and oxerutin: Effectiveness of combination therapy

Phlebology

Volumn 25, Issue 2, 2010, Pages 66-71

  Akbulut, B ^a  

^a Kutahya Evliya Celebi State Hospital   (Turkey)

Author keywords

Calcium dobesilate; Combination therapy; Oxerutin; Venous insufficiency

Indexed keywords

DOBESILATE CALCIUM; MONOXERUTIN;

ADULT; ARTICLE; CHRONIC VEIN INSUFFICIENCY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE CRAMP; PARESTHESIA; PHYSICAL SENSITIVITY; PRIORITY JOURNAL; PRURITUS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SWELLING; TREATMENT OUTCOME;

ADULT; ANTICOAGULANTS; CALCIUM DOBESILATE; CHRONIC DISEASE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HEMOSTATICS; HUMANS; HYDROXYETHYLRUTOSIDE; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME; VENOUS INSUFFICIENCY;

EID: 77950430918     PISSN: 02683555     EISSN: 14333031     Source Type: Journal    
DOI: 10.1258/phleb.2009.008085     Document Type: Article

References (38)

1. Kurz X, Kahn SR, Abenhaim L, et al. Chronic venous disorders of the leg: epidemiology, outcomes, diagnosis and management. Summary of an evidence-based report of the VEINES task force. Venous Insufficiency Epidemiologic and Economic Studies. Int Angiol 1999; 18:83-102
2. Nicolaides AN. Cardiovascular Disease Educational and Research Trust; European Society of Vascular Surgery; The International Angiology Scientific Activity Congress Organization; International Union of Angiology; Union Internationale de Phlebologie at the Abbaye des Vaux de Cernay. Investigation of chronic venous insufficiency: A consensus statement (France, March 5-9, 1997). Circulation 2000;102:E126-63
3. Stanhope JM. Varicose veins in a population of lowland New Guinea. Int J Epidemiol 1975;4:221-225
4. Van den Oever R, Hepp B, Debbaut B, Simon I. Socioeconomic impact of chronic venous insufficiency. An underestimated public health problem. Int Angiol 1998;17:161-167
5. Brand FN, Dannenberg AL, Abbott RD, Kannel WB. The epidemiology of varicose veins: the Framingham Study. Am J Prev Med 1988;4:96-101
6. Carpentier PH. Epidemiology and physiopathology of chronic venous leg diseases. Rev Prat 2000;50:1176-1181
7. Porter JM, Moneta GL. Reporting standards in venous disease: an update. International Consensus Committee on Chronic Venous Disease. J Vasc Surg 1995; 21:635-645
8. Tsouderos Y. Venous tone: are the phlebotonic properties predictive of a therapeutic benefit? A comprehensive view of our experience with Daflon 500 mg. Z Kardiol 1991;80(Suppl. 7):95-101
9. Behar A, Lagrue G, Cohen-Boulakia F, Baillet J. Capillary filtration in idiopathic cyclic edema - effects of Daflon 500 mg. Nuklearmedizin 1988;27:105-107
10. Ibáñez L, Ballarín E, Vidal X, Laporte JR. Agranulocytosis associated with calcium dobesilate clinical course and risk estimation with the case-control and the case-population approaches. Eur J Clin Pharmacol 2000; 56:763-767
11. Beckers C, Zijilstra JA. New aspects of the pathogenesis of CVI and the site of action of Venoruton. Phlebol Dig 2001;14:8-11
12. Belcaro G, Rulo A, Candiani C. Evaluation of the microcirculatory effects of Venoruton in patients with chronic venous hypertension with laser Doppler flowmetry, transcutaneous PO2 and PCO2 measurements, leg volumetry and ambulatory venous pressure measurements. Phlebology 1989;4:23-26
13. Cesarone MR, Laurora G, Ricci A, et al. Acute effects of hydroxyethylrutosides on capillary filtration in normal volunteers, patients with venous hypertension and in patients with diabetic microangiopathy (a dose comparison study). VASA 1992;21:76-80
14. Belcaro G, Errichi BM. Evaluation of capillary permeability in patients with venous hypertension treated with Venoruton® by the vacuum suction chamber (VSC) device. Phlebologie 1988;41:847-849
15. Incandela L, Belcaro G, Renton S, et al. HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides) in venous hypertensive microangiopathy: a prospective, placebo-controlled, randomized trial. J Cardiovasc Pharmacol Ther 2002;7(Suppl. 1):S7-10
16. Incandela L, Cesarone MR, DeSanctis MT, Belcaro G, Dugall M, Acerbi G. Treatment of diabetic microangiopathy and edema with HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides): a prospective, placebo-controlled, randomized study. J Cardiovasc Pharmacol Ther 2002;7(Suppl. 1):S11-5
17. Cesarone MR, Belcaro G, Incandela L, et al. Flight microangiopathy in medium-to-long distance flights: prevention of edema and microcirculation alterations with HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)- rutosides): a prospective, randomized, controlled trial. J Cardiovasc Pharmacol Ther 2002;7(Suppl. 1):S17-20
18. Cesarone MR, Incandela L, DeSanctis MT, et al. Treatment of edema and increased capillary filtration in venous hypertension with HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides): a clinical, prospective, placebo-controlled, randomized, dose-ranging trial. J Cardiovasc Pharmacol Ther 2002;7(Suppl. 1):S21-4
19. Rehn D, Unkauf M, Klein P, Jost V, Lücker PW. Comparative clinical efficacy and tolerability of oxerutins and horse chestnut extract in patients with chronic venous insufficiency. Arzneimittelforschung 1996;46: 483-487
20. Garay RP, Hannaert P, Chiavaroli C. Calcium dobesilate in the treatment of diabetic retinopathy. Treat Endocrinol 2005;4:221-232
21. Tejerina T, Ruiz E. Calcium dobesilate: pharmacology and future approaches. Gen Pharmacol 1998;31:357-360
22. Brunet J, Farine JC, Garay RP, Hannaert P. Angioprotective action of calcium dobesilate against reactive oxygen species-induced capillary permeability in the rat. Eur J Pharmacol 1998;358:213-220
23. Suschek C, Kolb H, Kolb-Bachofen V. Dobesilate enhances endothelial nitric oxide synthase-activity in macro- and microvascular endothelial cells. Br J Pharmacol 1997;122:1502-1508
24. Falkay G, Kovacs L. Calcium dobesilate (Doxium) as a prostaglandin synthetase inhibitor in pregnant human myometrium in vitro. Experientia 1984;40:190-191
25. Casley-Smith JR, Casley-Smith JR. The effects of calcium dobesilate on acute lymphedema (with and without macrophages), and on burn edema. Lymphology 1985;18:37-45
26. Casley-Smith JR. The influence of tissue hydrostatic pressure and protein concentration on fluid and protein uptake by diaphragmatic initial lymphatics; effect of calcium dobesilate. Microcirc Endothelium Lymphatics 1985;2:385-415
27. Piller NB. The lymphogogue action of calcium dobesilate on the flow of lymph from the thoracic duct of anesthetized and mobile guinea pigs. Lymphology 1988;21:124-127
28. Lameynardie S, Chiavaroli C, Travo P, Garay RP, Parés- Herbuté N. Inhibition of choroidal angiogenesis by calcium dobesilate in normal Wistar and diabetic GK rats. Eur J Pharmacol 2005;510:149-156
29. Rota R, Chiavaroli C, Garay RP, Hannaert P. Reduction of retinal albumin leakage by the antioxidant calcium dobesilate in streptozotocin-diabetic rats. Eur J Pharmacol 2004;495:217-224
30. Flota-Cervera F, Flota-Ruiz C, Treviño C, Berber A. Randomized, double blind, placebo-controlled clinical trial to evaluate the lymphagogue effect and clinical efficacy of calcium dobesilate in chronic venous disease. Angiology 2008;59:352-356
31. Martínez-Zapata MJ, Moreno RM, Gich I, Urrútia G, Bonfill X, Chronic Venous Insufficiency Study Group. A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease. Eur J Vasc Endovasc Surg 2008;35:358-365
32. Petruzzellis V, Troccoli T, Candiani C, et al. Oxerutins (Venoruton): efficacy in chronic venous insufficiency - a double-blind, randomized, controlled study. Angiology 2002;53:257-263
33. Allain H, Ramelet AA, Polard E, Bentue-Ferrer D. Safety of calcium dobesilate in chronic venous disease, diabetic retinopathy and haemorrhoids. Drug Saf 2004;27:649-660
34. Cesarone MR, Belcaro G, Ricci A, et al. Prevention of edema and flight microangiopathy with Venoruton (HR), (0-[beta-hydroxyethyl]-rutosides) in patients with varicose veins. Angiology 2005;56:289-293
35. Cesarone MR, Belcaro G, Pellegrini L, et al. HR, 0-(beta-hydroxyethyl)- rutosides; (Venoruton): rapid relief of signs/symptoms in chronic venous insufficiency and microangiopathy: a prospective, controlled study. Angiology 2005;56:165-172
36. Belcaro G, Cesarone MR, Bavera P, et al. HR (Venoruton 1000, Paroven, 0-[beta-hydroxyethyl]-rutosides) vs. Daflon 500 in chronic venous disease and microangiopathy: an independent prospective, controlled, randomized trial. J Cardiovasc Pharmacol Ther 2002;7:139-145
37. de Jongste AB, Jonker JJ, Huisman MV, ten Cate JW, Azar AJ. A double blind three center clinical trial on the short-term efficacy of 0-(beta-hydroxyethyl)-rutosides in patients with post-thrombotic syndrome. Thromb Haemost 1989;62:826-829
38. Bergqvist D, Hallböök T, Lindblad B, Lindhagen A. A double-blind trial of 0-(beta-hydroxyethyl)-rutoside in patients with chronic venous insufficiency. VASA 1981;10:253-260